Advertisement

Management of Beta Blocker and Calcium Channel Blocker Toxicity

  • Daniel Overbeek
  • Robert W. ShafferEmail author
Chapter
  • 3 Downloads

Abstract

The management of beta-blocker and calcium-channel blocker overdoses may be challenging with a high incidence of morbidity and mortality (Love et al., J Toxicol Clin Toxicol 35:353–359, 1997). Calcium-channel blocker poisonings are the leading cause of death from cardiovascular medication overdoses (Gummin et al., Clin Toxicol 55:1072–1254, 2017; Shenoy et al., J Hosp Med 9:663–668, 2014). Clinical effects in poisoned patients may include hypotension, bradycardia, atrioventricular conduction disturbances, seizures, altered mental status, profound shock, coma and death. Due to the wide variety of preparations available, toxicokinetics are highly variable. These medications are generally lipophilic and protein bound, and therefore extracorporeal elimination methods are largely ineffective (Kerns, Emerg Med Clin North Am 25:309–331, 2007).

Beta-blockers antagonize the beta-adrenergic receptor in a competitive manner. At therapeutic doses, this is intended to decrease hypertension, tachycardias, myocardial oxygen demand and myocardial remodeling (Waagstein et al., Br Heart J 37:1022–1036, 1975). There are a wide variety of beta-blockers, some of which are selective antagonists of either the beta-1 or beta-2 receptors. However, most lose their selectivity at toxic levels (DeWitt and Waksman, Toxicol Rev 23:223–238, 2004). Propanolol has a relatively higher prevalence of intentional overdose and death, likely related to its use for anxiety and migraines which may lead to more prescriptions in populations at higher risk for intentional overdose (Reith et al., J Toxicol Clin Toxicol 34:273–278, 1996).

Calcium-channel blockers act at L-type calcium channels and are generally divided into two unique pharmacologic classes based on preferred sites of actions (Table 7.1). Dihydropyridine (i.e. amlodipine) overdose primarily cause hypotension through peripheral vasodilatory effects, with reflex tachycardia. Non-dihydropyridines (i.e. diltiazem and verapamil) often cause more severe toxicity, with primary effects on the myocardium (Siddiqi et al., Respir Care 59:e15–21, 2014). Calcium-channel blockers also lose their selectivity in severe poisonings (Shenoy et al., J Hosp Med 9:663–668, 2014).

The general effects of both overdoses are similar and tend to lead to bradydysrhythmias, depressed myocardial contractility, and subsequent profound hypotension and shock causing circulatory collapse. Treatment of these overdoses tends to follow the same pathways. Therefore, we will discuss their management together, and specifically identify when components of the management differ between beta-blockers and calcium-channel blockers.

Traditional therapies include the administration of IV fluids, calcium salts, glucagon and vasopressors. Bradycardia and atrioventricular nodal blockade may necessitate the use of atropine or temporary pacemakers, and these treatments have inconsistent effectiveness. High-dose insulin euglycemia therapy shows great promise with strong evidence supporting its use. In certain cases, extracorporeal membrane oxygenation support (ECMO) may be an option for refractory shock and cardiac collapse.

Keywords

Overdose Toxicology Calcium channel blocker Beta blocker Glucagon High-dose insulin euglycemia Intralipid Shock 

References

  1. 1.
    Shenoy S, Lankala S, Adigopula S. Management of calcium channel blocker overdoses. J Hosp Med. 2014;9(10):663–8.  https://doi.org/10.1002/jhm.2241.CrossRefPubMedGoogle Scholar
  2. 2.
    Lapatto-Reiniluoto O, Kivistö KT, Neuvonen PJ. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther. 2001;70(3):255–60.  https://doi.org/10.1067/mcp.2001.118184.CrossRefPubMedGoogle Scholar
  3. 3.
    Jang DH, Spyres MB, Fox L, Manini AF. Toxin-induced cardiovascular failure. Emerg Med Clin North Am. 2014;32(1):79–102.  https://doi.org/10.1016/j.emc.2013.10.003.CrossRefPubMedGoogle Scholar
  4. 4.
    St-Onge M, Dubé P-A, Gosselin S, et al. Treatment for calcium channel blocker poisoning: a systematic review. Clin Toxicol. 2014;52(9):926–44.  https://doi.org/10.3109/15563650.2014.965827.CrossRefGoogle Scholar
  5. 5.
    Cumpston KL, Aks SE, Sigg T, Pallasch E. Whole bowel irrigation and the hemodynamically unstable calcium channel blocker overdose: primum non nocere. J Emerg Med. 2010;38(2):171–4.  https://doi.org/10.1016/J.JEMERMED.2007.11.100.CrossRefPubMedGoogle Scholar
  6. 6.
    Buckley N, Dawson AH, Howarth D, Whyte IM. Slow-release verapamil poisoning. Use of polyethylene glycol whole-bowel lavage and high-dose calcium. Med J Aust. 1993;158(3):202–4. http://www.ncbi.nlm.nih.gov/pubmed/8450791. Accessed 18 Oct 2018CrossRefGoogle Scholar
  7. 7.
    Semler MW, Self WH, Wanderer JP, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018;378(9):829–39.  https://doi.org/10.1056/NEJMoa1711584.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. Crit Care Med. 2017;45(3):e306–15.  https://doi.org/10.1097/CCM.0000000000002087.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bailey B. Glucagon in β-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41(5):595–602.  https://doi.org/10.1081/CLT-120023761.CrossRefPubMedGoogle Scholar
  10. 10.
    Papadopoulos J, O’Neil MG. Utilization of a glucagon infusion in the management of a massive nifedipine overdose. J Emerg Med. 2000;18(4):453–5.  https://doi.org/10.1016/S0736-4679(00)00163-3.CrossRefPubMedGoogle Scholar
  11. 11.
    McLean M, Van Donselaar K, Thomas P, Tilney PVR. A 42-year-old woman with a beta blocker overdose. Air Med J. 2018;37(3):147–50.  https://doi.org/10.1016/J.AMJ.2017.11.001.CrossRefPubMedGoogle Scholar
  12. 12.
    Levine M, Curry SC, Padilla-Jones A, Ruha A-M. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann Emerg Med. 2013;62(3):252–8.  https://doi.org/10.1016/j.annemergmed.2013.03.018.CrossRefPubMedGoogle Scholar
  13. 13.
    Kerns W. Management of β-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25(2):309–31.  https://doi.org/10.1016/j.emc.2007.02.001.CrossRefPubMedGoogle Scholar
  14. 14.
    Avery GJ 2nd, Spotnitz HM, Rose EA, Malm JR, Hoffman BF. Pharmacologic antagonism of beta-adrenergic blockade in dogs, I: hemodynamic effects of isoproterenol, dopamine, and epinephrine in acute propranolol administration. J Thorac Cardiovasc Surg. 1979;77(2):267–76.CrossRefGoogle Scholar
  15. 15.
    Siddiqi TA, Hill J, Huckleberry Y, Parthasarathy S. Non-cardiogenic pulmonary edema and life-threatening shock due to calcium channel blocker overdose: a case report and clinical review. Respir Care. 2014;59(2):e15–21.  https://doi.org/10.4187/respcare.02244.CrossRefPubMedGoogle Scholar
  16. 16.
    Engebretsen KM, Kaczmarek KM, Morgan J, Holger JS. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol. 2011;49:277–83.  https://doi.org/10.3109/15563650.2011.582471.CrossRefGoogle Scholar
  17. 17.
    Woodward C, Pourmand A, Mazer-Amirshahi M. High dose insulin therapy, an evidence based approach to beta blocker/calcium channel blocker toxicity. DARU. 2014;22(1):36.  https://doi.org/10.1186/2008-2231-22-36.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Weissler AM, Altschuld RA, Gibb LE, Pollack ME, Kruger FA. Effect of insulin on the performance and metabolism of the anoxic isolated perfused rat heart downloaded from. Circ Res. 1973;77:108–16. http://circres.ahajournals.org/. Accessed October 18, 2018CrossRefGoogle Scholar
  19. 19.
    Farah AE, Alousi AA. The actions of insulin on cardiac contractility. Life Sci. 1981;29(10):975–1000.  https://doi.org/10.1016/0024-3205(81)90457-4.CrossRefPubMedGoogle Scholar
  20. 20.
    Holger JS, Stellpflug SJ, Cole JB, Harris CR, Engebretsen KM. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol. 2011;49(7):653–8.  https://doi.org/10.3109/15563650.2011.593522.CrossRefGoogle Scholar
  21. 21.
    Greene SL, Gawarammana I, Wood DM, Jones AL, Dargan PI. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007;33(11):2019–24.  https://doi.org/10.1007/s00134-007-0768-y.CrossRefPubMedGoogle Scholar
  22. 22.
    DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004;23(4):223–38.  https://doi.org/10.2165/00139709-200423040-00003.CrossRefPubMedGoogle Scholar
  23. 23.
    Kline JA, Raymond RM, Schroeder JD, Watts JA. The diabetogenic effects of acute verapamil poisoning. Toxicol Appl Pharmacol. 1997;145(2):357–62.  https://doi.org/10.1006/TAAP.1997.8195.CrossRefPubMedGoogle Scholar
  24. 24.
    Place R, Carlson A, Leiken J, Hanashiro P. Hyperinsulin therapy in the treatment of verapamil overdose. J Toxicol Clin Toxicol. 2000;38(5):576–7.Google Scholar
  25. 25.
    Jang DH, Nelson LS, Hoffman RS. Methylene blue in the treatment of refractory shock from an amlodipine overdose. Ann Emerg Med. 2011;58(6):565–7.  https://doi.org/10.1016/J.ANNEMERGMED.2011.02.025.CrossRefPubMedGoogle Scholar
  26. 26.
    McGlinchey PG, McNeill AJ. Drug overdoses requiring temporary cardiac pacing; a study of six cases treated at Altnagelvin Hospital, Londonderry. Ulster Med J. 1998;67(1):13–8. http://www.ncbi.nlm.nih.gov/pubmed/9652193. Accessed 25 Aug 2018PubMedPubMedCentralGoogle Scholar
  27. 27.
    Kolcz J, Pietrzyk J, Januszewska K, Procelewska M, Mroczek T, Malec E. Extracorporeal life support in severe propranolol and verapamil intoxication. J Intensive Care Med. 2007;22(6):381–5.  https://doi.org/10.1177/0885066607307528.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang GS, Levitan R, Wiegand TJ, Lowry J, Schult RF, Yin S. Extracorporeal membrane oxygenation (ECMO) for severe toxicological exposures: review of the toxicology investigators consortium (ToxIC). J Med Toxicol. 2016;12:95–9.  https://doi.org/10.1007/s13181-015-0486-8.CrossRefPubMedGoogle Scholar
  29. 29.
    Baud FJ, Megarbane B, Deye N, Leprince P. Clinical review: aggressive management and extracorporeal support for drug-induced cardiotoxicity. Crit Care. 2007;11(2):207.  https://doi.org/10.1186/cc5700.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Harvey M, Cave G. Lipid emulsion in local anesthetic toxicity. Curr Opin Anaesthesiol. 2017;30(5):632–8.  https://doi.org/10.1097/ACO.0000000000000498.CrossRefPubMedGoogle Scholar
  31. 31.
    Cave G, Harvey M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med. 2009;16(9):815–24.  https://doi.org/10.1111/j.1553-2712.2009.00499.x.CrossRefPubMedGoogle Scholar
  32. 32.
    French D, Armenian P, Ruan W, et al. Serum verapamil concentrations before and after Intralipid® therapy during treatment of an overdose. Clin Toxicol. 2011;49(4):340–4.  https://doi.org/10.3109/15563650.2011.572556.CrossRefGoogle Scholar
  33. 33.
    Young AC, Velez LI, Kleinschmidt KC. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. Resuscitation. 2009;80(5):591–3.  https://doi.org/10.1016/J.RESUSCITATION.2009.01.023.CrossRefPubMedGoogle Scholar
  34. 34.
    Jamaty C, Bailey B, Larocque A, Notebaert E, Sanogo K, Chauny J-M. Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. Clin Toxicol. 2010;48(1):1–27.  https://doi.org/10.3109/15563650903544124.CrossRefGoogle Scholar
  35. 35.
    Doepker B, Healy W, Cortez E, Adkins EJ. High-dose insulin and intravenous lipid emulsion therapy for cardiogenic shock induced by intentional calcium-channel blocker and beta-blocker overdose: a case series. J Emerg Med. 2014;46(4):486–90.  https://doi.org/10.1016/J.JEMERMED.2013.08.135.CrossRefPubMedGoogle Scholar
  36. 36.
    Liang CW, Diamond SJ, Hagg DS. Lipid rescue of massive verapamil overdose: a case report. J Med Case Rep. 2011;5(1):399.  https://doi.org/10.1186/1752-1947-5-399.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Cao D, Heard K, Foran M, Koyfman A. Intravenous lipid emulsion in the emergency department: a systematic review of recent literature. J Emerg Med. 2015;48(3):387–97.  https://doi.org/10.1016/J.JEMERMED.2014.10.009.CrossRefPubMedGoogle Scholar
  38. 38.
    Lee HMD, Archer JRH, Dargan PI, Wood DM. What are the adverse effects associated with the combined use of intravenous lipid emulsion and extracorporeal membrane oxygenation in the poisoned patient? Clin Toxicol. 2015;53(3):145–50.  https://doi.org/10.3109/15563650.2015.1004582.CrossRefGoogle Scholar
  39. 39.
    Aggarwal N, Kupfer Y, Seneviratne C, Tessler S. Methylene blue reverses recalcitrant shock in β-blocker and calcium channel blocker overdose. BMJ Case Rep. 2013;  https://doi.org/10.1136/bcr-2012-007402.
  40. 40.
    Pichon N, Dugard A, Clavel M, Amiel JB, François B, Vignon P. Extracorporeal albumin dialysis in three cases of acute calcium channel blocker poisoning with life-threatening refractory cardiogenic shock. Ann Emerg Med. 2012;59(6):540–4.  https://doi.org/10.1016/J.ANNEMERGMED.2011.07.029.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Emergency MedicineMichigan MedicineAnn ArborUSA

Personalised recommendations